Point-of-Care Platelet Agglutination Assay Against Clumping Errors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for quantifying platelet concentration in blood samples are inadequate for point-of-care applications, particularly in determining the cause of bleeding issues due to low platelet function or number, and do not effectively prevent platelet activation and non-specific clumping.
Innovation Solution
The use of solid substrate-antibody conjugates, combined with protease inhibitors, inhibitors of platelet activation, stabilizing agents, and inhibitors of non-specific binding, to quantify platelets by agglutination, facilitated by antibodies specific to platelet cell surface receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional platelet counting methods are used, then platelet concentration can be measured, but platelet activation and non-specific clumping occur leading to measurement errors
Solution Approach 1:
The patent applies preliminary anti-action by incorporating protease inhibitors and platelet activation inhibitors into the assay composition before the measurement process begins. These inhibitors preemptively prevent platelet activation and non-specific clumping that would otherwise occur during the counting process, thereby eliminating the source of measurement errors before they can affect the results.
Solution Approach 2:
The patent uses an intermediary approach by introducing Fc block antibodies that specifically bind to Fc receptors on platelets. This intermediary substance prevents non-specific binding of the detection antibodies to platelets through Fc receptor mediation, thereby eliminating a major source of measurement error while allowing specific antigen-antibody interactions to proceed.
2Productivity
If rapid point-of-care testing is implemented, then timely intervention is enabled, but measurement accuracy may be compromised
Solution Approach 1:
The patent applies preliminary action by pre-formulating the assay composition with all necessary protective agents (protease inhibitors, platelet activation inhibitors, Fc block) already incorporated into a ready-to-use kit. This preliminary preparation eliminates the need for complex sample processing steps during the actual test, enabling rapid point-of-care testing while maintaining measurement accuracy through the pre-installed protective mechanisms.
Solution Approach 2:
The patent merges multiple functions into a single integrated assay composition that simultaneously provides platelet counting capability, platelet activation inhibition, protease protection, and non-specific binding prevention. This consolidation allows the entire assay to be performed in a single rapid step at the point of care without sacrificing accuracy, as all protective mechanisms are already combined in the reagent formulation.
3Measurement precision
If multiple inhibitors and agents are added to prevent platelet activation, then measurement accuracy improves, but assay complexity increases
Solution Approach 1:
The patent applies universality by designing a single multi-functional assay composition that simultaneously performs platelet counting, prevents platelet activation, inhibits proteases, and blocks non-specific binding. All these functions are integrated into one reagent formulation that can be added to the blood sample in a single step, thereby maintaining measurement accuracy while minimizing the operational complexity of the assay procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and sensitive measurement of platelet counts at the point of care, reducing errors from platelet activation and clumping, and facilitating timely intervention for bleeding disorders.
Implementation Method 1
the antibody has binding specificity for a platelet cell surface receptor (e.g., a glycoprotein receptor) such that platelets in the blood sample can bind to the solid substrate-antibody conjugates
Implementation Method 2
subjecting the blood sample/solid substrate-antibody combination to agglutination conditions. Agglutination of the conjugates can be measured as an indication of the number of platelets present in the blood sample
Data Source
AI summary
Methods and materials that can be used to measure the concentration of platelets in whole blood samples (e.g., at the point of care) are provided herein.